This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
Exact Sciences Corp. announced that the company continued its strong performance during the third quarter ended Sept. 30, 2015, completing 34,000 Cologuard tests, an increase of 60 percent from the second quarter, which resulted in $12.6 million in revenues. The cumulative number of ordering physicians grew to 21,000 during the quarter, an increase of 42 percent.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Exact Sciences Corp. announced that the company continued its strong performance during the third quarter ended Sept. 30, 2015, completing 34,000 Cologuard tests, an increase of 60 percent from the second quarter, which resulted in $12.6 million in revenues. The cumulative number of ordering physicians grew to 21,000 during the quarter, an increase of 42 percent.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
The Latest Regulations, Simplified: MU, PQRS & MIPSathenahealth
Changing governmental regulations for the advancement of healthcare is more than difficult and we have simplified these changes to keep you up to date.
Corporate Presentation TiGenix - September 2014TiGenix
This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.
This document may contain forward-looking statements and estimates made by the Company, including with respect to the anticipated future performance of TiGenix and the market in which it operates. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this document and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based.
Advisor Live: Advancing Antimicrobial StewardshipPremier Inc.
Fight antibiotic resistance! Join us and participate in Get Smart About Antibiotics Week 2016. Medical epidemiologist Dr. Kavita Trivedi will share her deep wealth of knowledge to help your organization implement and meet the challenges of antimicrobial stewardship.
- Current regulatory environment
- Implementation tools available
- Implementation challenges
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
A program that seeks to redefine best practice across the drivers of the GenesisCare business (Quality, Access and Efficiency) in order to deliver on their vision of “Innovating Healthcare. Transforming Lives.”
Health IT Summit Houston 2014 - Case Study "EHR Optimization for Organizational Value in a Changing Healthcare Environment"
Luis Saldana, MD, MBA, FACEP
CMIO
Texas Health Resources
iHT2 case studies and presentations illustrate challenges, successes and various factors in the outcomes of numerous types of health IT implementations. They are interactive and dynamic sessions providing opportunity for dialogue, debate and exchanging ideas and best practices. This session will be presented by a thought leader in the provider, payer or government space.
3. 3
The information and data presented here was prepared for
investors and potential investors. It includes forward-looking
information on investigational products in development that are
not available for sale in the United States. These include early-
stage development products for which the performance
characteristics have not yet been established.
4. Source: ACS Cancer Facts & Figures 2015; all figures annual
Colorectal cancer:
Second most lethal cancer in US
new diagnoses in 2015
14,180 15,590
27,540
40,560 40,730
49,700
158,040Annual US cancer mortality
132,700
Deaths in 2015
49,700
5. Source: CDC MMWR 2013; 64(17);464-468 (Sabatino)
Many Americans aren’t getting screened for
colon cancer
42%
of Americans not current on
colon cancer screening
7. Source: N Engl J Med 2014;370:1287-97. DOI 10.1056/NEJMoa1311194 (Imperiale)
Cologuard® proven in unprecedented study
8. Cologuard®: Detecting cancer when most treatable
1,000
50 people with
pre-cancers,
all removable
6 people
with cancer
5 with
early stage
disease
9. Pathways to mobilizing Cologuard® adoption
Influencing
Physicians
Securing
Coverage
Activating
People
10. Pathways to mobilizing Cologuard® adoption
Influencing
Physicians
Securing
Coverage
Activating
People
11. 160
High quality sales force generating results
200
Sales Reps on June 1
Creating a results-driven field force
Strategically aligned co-promote partner
Average 10 years sales experience
Focused on high-value physicians
Real-time data guides strategy
12. Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun
Number of physicians ordering Cologuard® rapidly expanding
13,800 ordering physicians as of June 19
Adding ~500
new physicians weekly
The illustration includes data as of June 19th and
the month of June is extrapolated through June 30th
13. 75%of volume driven by sales
Marketing driving awareness; sales driving volume
Marketing
generating
57%
First-time ordering physicians
43% Sales and systems
generating
The illustration is launch to date as of June 12th
14. Number of Cologuard® completed tests
consistently rising
4,000
11,000
21,000
Q4 Q1 Q2
Tests completed
Q2 results estimated based on actuals as of June 22nd
~
15. Factors that shape Cologuard® ordering
• Physicians need
– Awareness
– Coverage
– Quality metrics inclusion
– Easy to order and get
results (EMR linkage)
16. Substantial underlying demand supports growth
~80,000
orders
through Q2
• Converting orders into
completed tests need
– Time to perform test (~30 days)
– Complete information on order
– Insurance coverage
– 73% compliance rate
17. Most physicians order Cologuard® more than once
63%
of ordering physicians order
Cologuard® more than once
Includes providers whose first order was on or before May 5th, 2015
18. Number of new-ordering and repeat-ordering
physicians growing consistently
23 333
1,359
2,862
4,098
5,316
6,610
8,402
10,472
12,095
13,082
Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15
# of Orders
Monthly
Growth Rate
35%
25%
20%Ordered 1
Ordered 2-4
Ordered 5+
The illustration is launch to date as of June 19th
19. Investment in proprietary systems driving
business strategy
Sales -
CRM
Call
Center
Lab
Information
System
Electronic
Data
Warehouse
21. Propriety software enables
Monitoring orders and results
in real-time
Engaging targeted physicians
to maximize ordering
Ensuring timely follow-up to new,
‘untouched’ prescribers
Tracking Cologuard® progress
from prescription to result
Real-time visibility drives Cologuard® sales
22. Cologuard® launch early takeaways
• Targeting
– Targets are just as likely to order as non-targets
– Targets order 17% more than non-targets
– Real-time data driving targeting
23. Cologuard® launch early takeaways
• Sales frequency drives ordering
– 3.6 calls on average before a physician orders Cologuard®
Frequency of sales activity after provider’s first order
Never Monthly Twice per month
Orders per week
99%
66%
For providers ordering prior to May 22, 2015
24. Investment in health systems
• 30 health systems have adopted the use of Cologuard®
in their colon cancer screening programs
• 11 additional health systems are currently active in the
implementation process
• ~5,000 PCPs have management support and the ability to order
Cologuard® through their electronic medical record system
25. Significant opportunity ahead for Cologuard®
“When my rep told me
about the noninvasive test
with no prep, the high
sensitivity, the 10,000
person study to back that
up, I was sold. He also
helped get me registered
and set up in the system so
I was ready to go.”
– Prescribing Physician
Cologuard®
sales reaching
~ 40,000 PCPs today
240,000 PCPs
26. Source: Medical education program since January 2015
Medical education working and supports
continued investment
>152 dinner events conducted
with >2,017 attendees
25,220 viewers of Medscape
CME program (as of June 15th)
Presence at 7 national medical
congresses since launch Lunch & Learns
1,904
27. Pathways to mobilizing Cologuard® adoption
Influencing
Physicians
Securing
Coverage
Activating
People
30. Identified pilot markets based on population of patients with insurance
coverage and critical mass of Cologuard® ordering physicians
Pilot of regional marketing campaigns
Pittsburgh Florida Gulf Phoenix
Baltimore Washington,
D.C.
Boston
31. Expanded marketing in these regions
driving increased orders
BillboardsPrint Radio Digital PR
32. Pathways to mobilizing Cologuard® adoption
Influencing
Physicians
Securing
Coverage
Activating
People
33. Securing reimbursement through two steps
Commitment by payer to cover
Cologuard® at undefined rate1. Coverage
In-network rate that absolves
patient from payment2. Contracting
Commitment by payer to cover
Cologuard® at undefined rate1. Coverage
In-network rate that absolves
patient from payment2. Contracting
34. Current landscape for insured patients
50+ years of age
Medicare
46%
Commercial
Coverage for
Cologuard® 7%
Pursuing
Coverage
47%
35. • Active conversations with
200 key payers
• Building internal resources
dedicated to securing coverage
• Average commercial contracted
rate above Medicare rate ($493)
Growth strategy to expand coverage and contracting
Quality
of Care
NEJM publication – 92%
sensitive, Medicare NCD
Cost
Savings
Alternative to costly
colonoscopy
Member
Satisfaction
Easy, non-invasive test
and compliance program
Compelling payer value proposition
36. Guidelines promote use and expand coverage
Draft guidance expected
Q3 2015; final rating
expected in 2016
Included ACS guidelines
every 3 years
37. Ordering behavior expected to change with
USPSTF “A” or “B” rating
• Supports physicians ordering behavior
• HEDIS: National Committee on Quality
Assurance (NCQA)
• STARS: Medicare Advantage (CMS)
• Under Affordable Care Act, commercial
payers must cover Cologuard®
Quality Measures
Credit for screening
with Cologuard®
Commercial Coverage
Insurance payment
for Cologuard®
38. Regulatory approval
Validated clinical utility
Broad existing coverage
Recommended in guidelines
Cost savings
Cologuard®: A value proposition driving compliance
73%Cologuard®
compliance rate
The illustration is launch to date as of June 19th
39.
40. Adding new people to America’s screening population
36% screened with
colonoscopy only
Screening history of Cologuard® users
36% never
screened before
Source: Exact Sciences Laboratories LLC data (unpublished), n = 2,997
8% screened
with FIT/FOBT
20% screened
with colonoscopy
or FIT/FOBT
41. Cologuard® surpassing PCP diagnostic
product launches
0
10
20 Revenue increase in first
2 years of product launch
Revenue($MM)
Initial 2 years following launch
Cologuard®
ThinPrep
HPV DNA
42. Pathways to mobilizing Cologuard® adoption
Influencing
Physicians
Securing
Coverage
Activating
People